New combo therapy aims to shrink Hard-to-Treat neuroendocrine liver tumors

This phase 2 pilot study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with liver-directed treatments (like embolization or radiation) or peptide receptor radionuclide therapy (PRRT) can shrink tumors in people with well-differentiated neuroendocrine tumors that have spread to the liver. About 32 adults with symptomatic or growing liver metastases will receive one of three treatment combinations. The goal is to see if these combos work better than pembrolizumab alone, while monitoring side effects.